WuXi Vaccines Signs $3 Billion, 20-Year Agreement to Manufacture Vaccine

WuXi Vaccines finalized a $3 billion 20-year agreement with an unspecified "global vaccine leader" to manufacture a vaccine for the company. Last year, WuXi Vaccines, a joint venture comprised of WuXi Biologics and Shanghai Hile Bio-technology, began building a $240 million production facility in Ireland that will provide worldwide supplies of the vaccine. The facility is next to a major facility under construction for WuXi Biologics. WuXi and the unnamed vaccine maker expect the vaccine to produce $3 billion in revenues over 20 years. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues: